To address limitations with CAR T therapies targeting CD19, Allogene Therapeutics Inc. has developed ALLO-329, a ...

Researchers from Emory University, the U.S. CDC and collaborators have identified a broad-spectrum antiviral agent able to combat highly pathogenic arenaviruses. The compound, a ribonucleoside ...

Rectify Pharmaceuticals Inc. has conducted preclinical testing on RTY-694, an oral dual-targeted positive functional ...

The company analyzed genomic data provided by the Fred Hutch Cancer Center and compiled by the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) to identify mutational signatures and ...

Oxford Nanopore Technologies Ltd. has established a new collaboration with UK Biobank to create the world’s first ...

The FDA announced a new pilot program for communication of medical device recalls, but industry may be wary of a program that ...

The collaboration aims to identify a small molecule that targets mutant androgen receptor (AR) mRNA splicing and causes selective destruction of the disease-causing mRNA.

Potent siRNAs against B4GALT1 were designed in silico and screened in vitro (Huh7 cells, primary mouse, human hepatocytes) as well as in vivo (C57BL/6 mice) for the selection of a lead Galomic siRNA.

Researchers from SL Bigen Inc. and collaborators presented the preclinical characterization of BM-205, a novel entity of engineered MSCs designed to exert antitumor functions.

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Genzyme Corp. (Sanofi Genzyme) has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, multiple ...

Arovella Therapeutics Ltd. is heading toward the clinic with its lead product, ALA-101, which consists of a chimeric antigen receptor (CAR) targeting CD19 and invariant natural killer T (iNKT) cells.